MDT

96.72

-0.11%↓

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

MDT

96.72

-0.11%↓

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

MDT

96.72

-0.11%↓

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

MDT

96.72

-0.11%↓

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

MDT

96.72

-0.11%↓

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

Home・Aandelen Lijst・Kymera Therapeutics Inc

Kymera Therapeutics Inc

Gesloten

SectorGezondheidszorg

69.47 0.32

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

69.47

Max

69.47

Belangrijke statistieken
By Trading Economics
Inkomsten	-5.6M -82M
Verkoop	-8.7M 2.8M
Winstmarge	-2,973.046
Werknemers	225
EBITDA	5.2M -79M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+67.24% upside

Dividenden
By Dow Jones
Volgende Winsten	27 feb 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	1.6B 5.8B
Vorige openingsprijs	69.15
Vorige sluitingsprijs	69.47

Nieuwssentiment

By Acuity

20%

80%

30 / 361 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

28.34 / 33.56 Steun & Weerstand

Kymera Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

14 dec 2025, 08:30 UTC

Acquisities, Fusies, Overnames

Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. -- Barrons.com

Peer Vergelijking

Prijswijziging

Kymera Therapeutics Inc Prognose

Koersdoel

By TipRanks

67.24% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 116.3 USD 67.24%

Hoogste 138 USD

Laagste 90 USD

Gebaseerd op 22 Wall Street-analisten die 12-maands prijsdoelen bieden voor Kymera Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

22 ratings

Buy

Hold

Sell

Gebaseerd op 22 analisten die aandelenratings hebben gegeven aan Kymera Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

28.34 / 33.56Steun & Weerstand

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

Sentiment

By Acuity

30 / 361 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Kymera Therapeutics Inc

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.